Published in Gene Therapy Weekly, June 19th, 1995
Proceeds of the financing will support further development of the Aastrom Cell Production System (CPS), a proprietary, automated device that utilizes Aastrom's novel ex vivo stem and progenitor blood cell production technology.
Development milestones include further clinical trials in North America and Europe to assess the clinical efficacy of hematopoietic stem and progenitor cells produced by the Aastrom CPS. These "Ideal Transplant Cells" are intended to enhance patient recovery from immunosuppressive effects...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly